Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults
NCT05489328Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RSVpreF vaccine in pneumococcal disease (9 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Local Reactions Within 7 Days After Administration of Study Intervention, Percentage of Participants With Systemic Events Within 7 Days After Administration of Study Intervention and 2 more. Started Aug 2022; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05489328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489328.